Search and Alert Rationale

Discontinuation of Levemir® (Insulin detemir) Flexpen® and Penfill®

Levemir® insulin detemir injection 100 Units/mL

This site and associated resources have been funded by Novo Nordisk UK and developed in conjunction with Oberoi Consulting. They are intended for Healthcare Professionals (HCPs) and Other Relevant Decision Makers (ORDMs) who have population level decision making capability for their Healthcare Organisation. Clinical discretion should be exercised by the HCP to determine the best management plan for their patients.

The predefined searches and pop-up alerts have been aligned to the Primary Care Diabetes & Obesity Society (PCDOS) & Association of British Clinical Diabetologists (ABCD) guidance.[1] Novo Nordisk UK have had no involvement in the development of this guideline.

Search Title	Patient Search Population
Practice population	All currently registered patients
00. Patients with Levemir® (insulin detemir) Prescription in last 3 months	All patients prescribed Levemir® (insulin detemir) insulin in the last 3 months
01. Any Type of Diabetes and Pregnancy	Any type of diabetes and pregnancy, prescribed Levemir® (insulin detemir) insulin in the last 3 months
02. Any Type of Diabetes (25 and under)	Paediatric and adolescent diabetes of any type (Type 1, Type 2, Type 3c) under 25 years old, prescribed Levemir® (insulin detemir) insulin in the last 3 months
03. Adult Patients (over 25) with Type 1 or Type 3c Diabetes or Cystic Fibrosis related Diabetes (CFRD)	Adults (over 25) with Type 1 Diabetes, Type 3c Diabetes or Cystic Fibrosis related Diabetes (CFRD), prescribed Levemir® (insulin detemir) insulin in the last 3 months (including insulin pumps)
04. Adult Patients (over 25) with Type 2 Diabetes	Adults (over 25) with Type 2 Diabetes, prescribed Levemir® (insulin detemir) insulin in the last 3 months
05. Adult Patients (over 25) with Any Type of Diabetes with an eGFR <30ml/min	Adults (over 25) with any form of diabetes with an eGFR <30ml/min, prescribed Levemir® (insulin detemir) insulin in the last 3 months
06. Patients with Any Type of Diabetes not in any of the above	Any patient with diabetes, prescribed Levemir® (insulin detemir) insulin in the last 3 months, who do not fall into the above categories
07. Rx Levemir® (insulin detemir) current repeat, no DM coding	Any patient prescribed Levemir® (insulin detemir) insulin in the last 3 months who do not have a record of diabetes type recorded in their electronic records

1) Discontinuation of Levemir® (Insulin detemir) Flexpen® and Penfill® Clinical Guidance from the Primary Care Diabetes & Obesity Society (PCDOS) and Association of British Clinical Diabetologists (ABCD) Available at: https://cms.pcdosociety.org/uploads/Levemir_Discontinuation_Guideline_Final_110825_17d277acd3.pdf [last accessed: November 2025]

Adverse Event Reporting

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse Events should also be reported to Novo Nordisk UK (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Job Code: UK25LV00012 Date of Preparation: November 2025

Oberoi Technical Support

For any assistance or technical support for any part of the process contact the **Oberoi Technical Support**:

01156 715 770 **support@insulin-discontinuation.co.uk**

oberoi consulting

novo nordisk®